Specialty Pharmacy

Protein may potentially offer a future therapeutic target.

Takeda plans to target gastrointestinal and oncology medications in the near future.

Stopping smoking extends survival by nearly a year.

Top stories of the week on Specialty Pharmacy Times from July 13 to July 17.

Treatment improves overall survival.

Antibodies critical to stopping spread of viral cells.

T cells derived from lymph nodes expanded and activated in a laboratory before being injected back into patients.

By lowering LDL-C levels, alirocumab may reduce cardiovascular risk.

Study examines history of universal health care in the United States.

Shorter duration could reduce the economic impact on health care spending and make treatment more convenient.

Protein AKAP4 identified as the most accurate way to detect non-small cell lung cancer.

New culturing method leads to highly therapeutic cells that grow faster and stronger.

Methotrexate alone superior in efficacy to combination treatment with DMARDs.

Study finds that mitochondria of tumor cells are critical to survival and proliferation.

Five pivotal phase 3 trial ongoing for oral proteasome inhibitor.

Low dose methotrexate more likely to cause infectious adverse events than higher doses of the same drug.

Wait times for care negatively impacts patient health.

Envarsus protects against organ rejection in transplant patients who switch from other twice-daily tacrolimus products.

Pfizer executive discusses the present and future of biosimilars.

Research ongoing to target treatment-resistant gout.

Researchers evaluate why early trials of dasatinib did not give conclusive results.

Drug could be less expensive to produce and less harmful to healthy cells.

Mitali Nagrecha, counsel at Bergen Pharmacy, discusses tactics specialty pharmacies can use to maintain medication adherence.

Research finds a potential route for targeted therapies to inhibit development and progression.

Includes evidence-based advice on the best use for next generation direct-acting antivirals.

The first generic version of Valeant's bexarotene (Targretin) is now available from Mylan.

Pazopanib shows promise in soft tissue sarcoma patients.

Stem cells have been found to target inflammation in osteoarthritis or rheumatoid arthritis.